损耗
心理学
神经认知
干预(咨询)
焦虑
随机对照试验
人口
苦恼
生活质量(医疗保健)
临床心理学
萧条(经济学)
心理干预
认知
精神科
医学
心理治疗师
宏观经济学
外科
经济
牙科
环境卫生
作者
Therese V. Cash,Sarah K. Lageman
出处
期刊:BMC Psychology
[BioMed Central]
日期:2015-11-30
卷期号:3 (1): 44-44
被引量:14
标识
DOI:10.1186/s40359-015-0101-4
摘要
BACKGROUND: Individuals with Parkinson's disease (PD) and their caregivers are at risk for emotional distress and hypercortisolism. Expressive writing is an effective complementary intervention to ameliorate the psychological and physiological effects of chronic illness. This pilot study aimed to evaluate feasibility and preliminary effectiveness of an expressive writing intervention for individuals with PD and their caregivers. METHODS: Individuals with PD (N = 27) and their caregivers (N = 14) were randomly assigned to expressive (N = 15 patients, eight caregivers) or neutral (N = 12 patients, six caregivers) writing conditions. Cortisol awakening response (CAR), non-motor functioning, quality of life, and performance on tests of cognitive functioning were assessed at baseline, immediate post, 4-month, and 10-month post intervention. RESULTS: Attrition was a challenge as eight patients (29.62 %) and four caregivers (28.57 %) chose to discontinue before beginning the intervention or were lost to follow up prior to completing the intervention or the first follow up visit. Significant reduction in anxiety, marginally significant improvement in depression and caregiver burden, and significant improvements in performance on tests of learning and memory were observed, but these changes did not differ by writing condition. CAR significantly differed over time between patients and caregivers and writing conditions. CONCLUSIONS: Some evidence for the feasibility and effectiveness of writing to alleviate hypercortisolism was demonstrated in a small sample of PD patients; however, relatively high attrition rates and the lack of difference between expressive and neutral writing conditions on emotional and neurocognitive outcomes suggests expressive writing procedure modifications may be needed to obtain optimal results for this population. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02217735 , Study Start Date: August 30, 2011.
科研通智能强力驱动
Strongly Powered by AbleSci AI